Approximately 70% of all breast cancer patients have estrogen receptor-α (ERα) positive tumors, and are therefore often suited for endocrine therapies4, such as the ERα-inhibitor tamoxifen and the selective ERα-degrader fulvestrant. Here, ESR1 is linked to breast carcinoma.